Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease

Journal of Human Hypertension

Volumn 26, Issue 8, 2012, Pages 502-506

  Pisoni, R ^a   Acelajado, M C ^b   Cartmill, F R ^c   Dudenbostel, T ^b   Dell'Italia, L J ^b   Cofield, S S ^c   Oparil, S ^b   Calhoun, D A ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

aldosterone; chronic kidney disease; hyperkalemia; mineralocorticoid receptor antagonists; resistant hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; POTASSIUM; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMPOTENCE; MALE; POTASSIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

ACUTE KIDNEY INJURY; AGED; ALABAMA; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CREATININE; DIURETICS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; HYPERTENSION; KIDNEY; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; POTASSIUM; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863869088     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.60     Document Type: Article

References (23)

1. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of esrf in non-diabetic proteinuric chronic nephropathies. 'Gruppo italiano di studi epidemiologici in nefrologia' (gisen). Kidney Int 1998; 53: 1209-1216. (Pubitemid 28316881)
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. The JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
3. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
5. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patientlevel meta-analysis. Ann Intern Med 2003; 139: 244-252.
6. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170-2179. (Pubitemid 41716450)
7. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G et al. Independent and additive impact of blood pressure control and angiotensin ii receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037. (Pubitemid 44743500)
8. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845. (Pubitemid 351664214)
9. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930. (Pubitemid 37315491)
10. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438-441.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
12. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836. (Pubitemid 43251030)
13. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123. (Pubitemid 44871374)
14. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin ii receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
15. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ace inhibitors or angiotensin receptor blockers in ckd: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
16. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492. (Pubitemid 47313030)
17. MacGregor GA, Markandu ND, Rotellar C, Smith SJ, Sagnella GA. Different effect of nifedipine in normotensive and hypertensive individuals: a functional anomaly of vascular smooth muscle in essential hypertension? Rev Esp Cardiol 1983; 36: 473-477.
18. Ahuja TS, Freeman Jr D, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000; 20: 268-272.
19. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693. (Pubitemid 30140419)
20. Arima S. Aldosterone and the kidney: rapid regulation of renal microcirculation. Steroids 2006; 71: 281-285.
21. Loutzenhiser R, Griffin KA, Bidani AK. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens 2006; 15: 41-49.
22. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. African American Study of Kidney Disease and Hypertension Study Group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431. (Pubitemid 35340538)
23. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30: 418-424.